Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262443 | 0.91 | ABL1 (0.55) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL4266541 | 0.82 | ALDH1A1 (0.49) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL783033 | 0.82 | MAPK10 (0.49) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL4187385 | 0.81 | ABL1 (0.65) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL3562948 | 0.80 | CYP1A2 (0.47) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL4264785 | 0.80 | KARS1 (0.54) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL4268984 | 0.79 | ABL1 (0.60) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL4082500 | 0.79 | KDR (0.57) | ALDH1A1PRKCAABL1EGFRBCR | |
| SCHEMBL29364396 | 0.79 | ABL1 (0.69) | PRKCAABL1EGFRBCRSRC | |
| SCHEMBL30279956 | 0.79 | KDR (0.57) | ALDH1A1PRKCAABL1EGFRBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1533304-B1 | AMIDE DERIVATIVE | NIPPON SHINYAKU CO LTD (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7494997-B2 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20060014742-A1 | Amide derivative | NIPPON SHINYAKU CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1533304-A1 | AMIDE DERIVATIVE | Nippon Shinyaku Co., Ltd. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014742-A1 | Amide derivative | ABL1, ABL2, BCR | ALDH1A1 753/4885PRKCA 323/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.